Format

Send to

Choose Destination
Chem Biol Interact. 2018 Jun 1;289:68-74. doi: 10.1016/j.cbi.2018.04.023. Epub 2018 Apr 24.

Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase.

Author information

1
College of Oriental Medicine, Daegu Haany University, Gyeongsan, 38610, South Korea; College of Korean Medicine, Dongguk University, Gyeongju, 38066, South Korea.
2
College of Oriental Medicine, Daegu Haany University, Gyeongsan, 38610, South Korea.
3
College of Pharmacy, Chosun University, Gwangju, 61452, South Korea.
4
College of Oriental Medicine, Gachon University, Seongnam, Gyeonggido, 13120, South Korea.
5
Korea Institute of Oriental Medicine, Daegeon, 34054, South Korea.
6
College of Oriental Medicine, Daegu Haany University, Gyeongsan, 38610, South Korea. Electronic address: ywkim@dhu.ac.kr.

Abstract

Oxyresveratrol (OXY) is a naturally occurring polyhydroxylated stilbene that is abundant in mulberry wood (Morus alba L.), which has frequently been supplied as a herbal medicine. It has been shown that OXY has regulatory effects on inflammation and oxidative stress, and may have potential in preventing or curing nonalcoholic fatty liver disease (NAFLD). This study examined the effects of OXY on in vitro model of NAFLD in hepatocyte by the liver X receptor α (LXRα)-mediated induction of lipogenic genes and in vivo model in mice along with its molecular mechanism. OXY inhibited the LXRα agonists-mediated sterol regulatory element binding protein-1c (SREBP-1c) induction and expression of the lipogenic genes and upregulated the mRNA of fatty acid β-oxidation-related genes in hepatocytes, which is more potent than genistein and daidzein. OXY also induced AMP-activated protein kinase (AMPK) activation in a time-dependent manner. Moreover, AMPK activation by the OXY treatment helped inhibit SREBP-1c using compound C as an AMPK antagonist. Oral administration of OXY decreased the Oil Red O stained-positive areas significantly, indicating lipid droplets and hepatic steatosis regions, as well as the serum parameters, such as fasting glucose, total cholesterol, and low density lipoprotein-cholesterol in high fat diet fed-mice, as similar with orally treatment of atorvastatin. Overall, this result suggests that OXY has the potency to inhibit hepatic lipogenesis through the AMPK/SREBP-1c pathway and can be used in the development of pharmaceuticals to prevent a fatty liver.

KEYWORDS:

AMPK; Nonalcoholic fatty liver disease; Oxyresveratrol; SREBP-1c

PMID:
29702089
DOI:
10.1016/j.cbi.2018.04.023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center